Humanetics receives funding to study new drug for IPF

Graphic showing a pair of human lungs

Humanetics has been awarded a Small Business Innovation Research grant from the National Heart, Lung, and Blood Institute, a subsection of the National Institutes of Health, to support studies of a new drug for treating IPF.

The Humanetics project aims to evaluate the utility of BIO 300 as a treatment for IPF by measuring its ability to reduce pulmonary fibrosis in an accepted pre-clinical model of IPF. The studies supported by the new grant will provide the foundation for future work to support the translation of BIO 300 toward a clinical treatment for patients with IPF.

The drug, BIO 300, is believed to help prevent and mitigate acute and chronic inflammatory pulmonary diseases, including radiation toxicities. The studies will focus on the ability of BIO 300 to attenuate progressive pulmonary fibrosis as a potential treatment for IPF.

BIO 300 was discovered by researchers with the U.S. Department of Defense as a potential radio-protective drug for the military. It is currently under development by Humanetics as a countermeasure to protect the body from harm caused by ionizing radiation. The drug has been shown to mitigate inflammation of the lungs and pulmonary fibrosis caused by radiation. BIO 300 is also the subject of an ongoing phase 2 clinical trial in people hospitalized with acute respiratory disease syndrome caused by COVID-19.

Therapeutics have been approved by the FDA for the treatment of IPF based on their ability to slow the rate of lung function decline. Unfortunately, these treatments have not been shown to significantly alleviate IPF symptoms or improve patient quality of life. 

More in Pulmonary
Page 1 of 16
Next Page